HNS was approved by the U.S. Food and Drug Administration in 2014 as a treatment option for patients with moderate to severe OSA who cannot tolerate CPAP.


HNS was approved by the U.S. Food and Drug Administration in 2014 as a treatment option for patients with moderate to severe OSA who cannot tolerate CPAP.

Medullary thyroid carcinoma (MTC) comprises less than 5% of thyroid cancers but is responsible for more than 10% of deaths related to thyroid cancer.
Antithrombotic management is a key component of surgical optimization, as it necessitates balancing the risk of a peri-operative thrombotic event with the risk of bleeding.
Although en bloc resection remains the standard of care for primary treatment of oral cavity squamous cell carcinomas (OCSCC), methods of intra-operative assessment of margins vary.

Intracapsular tonsillectomy is a safe and effective method for performing tonsillectomy and should be included in future clinical practice guidelines for tonsillectomy.

Hypoglossal Nerve Stimulator therapy is an effective and safe surgical option for patients with moderate to severe OSA who cannot tolerate PAP therapy.

The use of p16 as a surrogate marker for HPV has gained traction, but is it sufficient as a surrogate for HPV-related squamous cell carcinoma?

The timing of tracheostomy tube changes should be tailored to each individual case.

Objective testing for patients with suspected LPR is indicated if the patient presents with typical alarm symptoms, after empiric treatment fails to improve symptoms, or to ensure the need for long-term therapy or surgical interventions.

Cochlear implant (CI) surgeons are faced with the increasingly difficult task of choosing the “right” device despite a growing number of choices and conflicting evidence regarding the relative importance of various anatomic, surgical, and device-specific factors.